Using immunotherapy to combat Klebsiella pneumoniae infections
Immunotherapy of KPC Infection
['FUNDING_R01'] · TULANE UNIVERSITY OF LOUISIANA · NIH-10671653
This study is looking at how a special type of treatment called immunotherapy can help fight tough infections caused by a bacteria called Klebsiella pneumoniae, especially for patients with weakened immune systems, by understanding how certain immune cells work to protect the body.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TULANE UNIVERSITY OF LOUISIANA (nih funded) |
| Locations | 1 site (NEW ORLEANS, UNITED STATES) |
| Trial ID | NIH-10671653 on ClinicalTrials.gov |
What this research studies
This research investigates the use of immunotherapy to treat infections caused by multi-drug resistant strains of Klebsiella pneumoniae, which pose a significant threat to patients, especially those with weakened immune systems. The study focuses on understanding how specific immune cells, such as NK cells and group 3 innate lymphoid cells, contribute to the body's defense against these infections. By analyzing the immune response in various models, the research aims to identify effective therapeutic strategies that could enhance patient outcomes. Patients with certain co-morbidities may benefit from targeted immunotherapy approaches developed through this research.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with compromised immune systems, such as those undergoing treatment for hematologic malignancies or those who have received organ transplants.
Not a fit: Patients with healthy immune systems and no underlying health conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new immunotherapy treatments that significantly improve recovery rates for patients suffering from severe Klebsiella pneumoniae infections.
How similar studies have performed: Previous research has shown promise in using immunotherapy to enhance immune responses against bacterial infections, suggesting that this approach could be effective for Klebsiella pneumoniae as well.
Where this research is happening
NEW ORLEANS, UNITED STATES
- TULANE UNIVERSITY OF LOUISIANA — NEW ORLEANS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KOLLS, JAY K — TULANE UNIVERSITY OF LOUISIANA
- Study coordinator: KOLLS, JAY K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Bacterial Infections, bacteria infection